Baseline characteristics
| Baseline characteristics (N = 32) . | n (%) . |
|---|---|
| Median age, y (range) | 35 (18-79) |
| Prior lines, median (range) | 3 (2-10) |
| Male | 22 (69) |
| White | 23 (72) |
| Black | 2 (6) |
| Asian | 1 (3) |
| Mixed race | 3 (9) |
| Not disclosed | 3 (9) |
| Hispanic | 9 (28) |
| Non-Hispanic | 21 (66) |
| Not disclosed | 2 (6) |
| Stage I or II | 8 (25) |
| Stage III or IV | 24 (75) |
| B symptoms | 4 (13) |
| Bulky disease (>5 cm) | 6 (19) |
| Extranodal involvement | 14 (44) |
| EBV+ | 4 (13) |
| EBV− | 16 (50) |
| EBV unknown | 12 (37) |
| Primary refractory | 22 (69) |
| Refractory to most recent therapy | 17 (53) |
| Prior BV | 30 (94) |
| BV refractory | 21 (66) |
| Prior PD-1 blockade | 25 (78) |
| PD-1 refractory | 18 (56) |
| Baseline characteristics (N = 32) . | n (%) . |
|---|---|
| Median age, y (range) | 35 (18-79) |
| Prior lines, median (range) | 3 (2-10) |
| Male | 22 (69) |
| White | 23 (72) |
| Black | 2 (6) |
| Asian | 1 (3) |
| Mixed race | 3 (9) |
| Not disclosed | 3 (9) |
| Hispanic | 9 (28) |
| Non-Hispanic | 21 (66) |
| Not disclosed | 2 (6) |
| Stage I or II | 8 (25) |
| Stage III or IV | 24 (75) |
| B symptoms | 4 (13) |
| Bulky disease (>5 cm) | 6 (19) |
| Extranodal involvement | 14 (44) |
| EBV+ | 4 (13) |
| EBV− | 16 (50) |
| EBV unknown | 12 (37) |
| Primary refractory | 22 (69) |
| Refractory to most recent therapy | 17 (53) |
| Prior BV | 30 (94) |
| BV refractory | 21 (66) |
| Prior PD-1 blockade | 25 (78) |
| PD-1 refractory | 18 (56) |
EBV, Epstein-Barr virus.